Company Overview - Arcuro Medical Ltd. is a portfolio company of The Trendlines Group, headquartered in Israel with operations in the U.S. [4] - The company specializes in developing and manufacturing minimally invasive orthopedic products, focusing on innovative medical devices [4]. - Arcuro Medical aims to improve patients' lives through game-changing technologies in sports medicine [4]. Investment Details - Varana Capital is the lead investor in Arcuro Medical's Series A financing round, which is currently open for additional investment [1]. - The funding will support Arcuro's growth and innovation in the medical device industry [1]. - Other notable investors in this round include Trendlines and Consensus Business Group [1]. Strategic Goals and Achievements - Arcuro Medical concluded 2024 with significant achievements, including the establishment of a new U.S. organization and hiring key sales leadership [5]. - The company added new U.S. and international distribution partners and achieved a significant product development milestone with the 510(k) submission of a new product line [5]. - Arcuro Medical surpassed 5,000 global SuperBall cases, positioning itself for substantial growth in 2025 [5]. Upcoming Events - Arcuro Medical will present at the MSK Innovations Pitch Event on January 8, 2025, providing insights into the company's vision and advancements [3].

Subscribers to Schaeffer's Weekend Trader options recommendation service received this GE commentary on Sunday night, along with a detailed options trade recommendation -- including complete entry and exit parameters. Learn more about why Weekend Trader is one of our most popular options trading services.Shares of GE Aerospace (NYSE:GE) recently cleared their 2005 and 2017 highs, and are pulling back to their 20-week and 126-day moving averages, both of which have led to outsized gains. Concerning the latte ...

Core Insights - ElastiMed Ltd. has appointed Dr. Amir Belson to its Board of Directors, enhancing its leadership in the wearable medical device sector [1][4] - Dr. Belson brings extensive experience in the medical device industry, having founded and led several successful companies that were acquired by major players [2][3] - His appointment is timely as ElastiMed aims to bring its innovative compression therapy devices to market, targeting millions suffering from lymphatic and venous diseases [3][4] Company Overview - ElastiMed specializes in wearable medical devices designed to treat and manage lymphatic and venous diseases, focusing on innovation and patient empowerment [5] - The company is committed to improving patient outcomes and addressing health equity challenges while enhancing healthcare delivery at home [5][6] - ElastiMed is a portfolio company of The Trendlines Group Ltd. and has received funding from various sources, including the Israeli Innovation Authority and Horizon 2020 [6]

Backed by IBF, Merz, and Laborie, Vensica to Advance Needle-Free Delivery of Botulinum Toxin A (Xeomin®) for Minimally Invasive TreatmentBROOKLYN, N.Y., Oct. 28, 2024 /PRNewswire/ -- Vensica Medical ("Vensica"), a pioneering urology therapeutics company, today announced the successful closing of an $11 million funding round. The investment will fund the company's upcoming Phase 2 clinical trials across the United States and Europe for its revolutionary treatment of overactive bladder (OAB) using botulinum t ...

FX Empire Logo English check-icon Italiano Español Português Deutsch العربية Français Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial ...

Meniscal Repair Innovator Continues U.S. Growth MINNEAPOLIS and MISGAV, Israel, Aug. 5, 2024 /PRNewswire/ -- Arcuro Medical Ltd., ("Arcuro") today announced a key milestone of exceeding 4,000 surgical cases worldwide, and 1,000 cases in the U.S., with its SuperBall™ Meniscal Repair System. The current version of the SuperBall Meniscal Repair System, commercially launched in 2022, with additional line extensions introduced in late 2023 addresses a full range of meniscus tear patterns. Jamal Rushdy, Arcuro's ...

Group 1 - Dominic (Dom) Serafino has been appointed as the Executive Chair of Dasyo, bringing extensive experience from his previous role as Co-Founder and CEO of Venus Concept Inc., where he led the company to over $100 million in annual revenues [1][2] - The appointment of Serafino is seen as a transformative step for Dasyo, aligning with the company's ambitious objectives in the aesthetics medical device sector [2] - Dasyo is focused on developing innovative non-surgical breast lift products utilizing proprietary technology for noninvasive directional skin tightening, supported by funding from the Israel Innovation Authority and The Trendlines Group [4] Group 2 - Serafino has a notable background, having been part of the executive team at Syneron Medical Corp, where he played a key role in the company's IPO, achieving a market cap of $1.3 billion within 18 months [5] - Serafino expressed confidence in Dasyo's innovative approach to aesthetics medical technologies, particularly in the non-surgical breast lifting category [6]

Core Insights - Ceretrieve's aspiration catheter has demonstrated the ability to remove clots and restore blood flow in a single pass, showcasing significant advancements in stroke treatment [1][2][4] Company Overview - Ceretrieve aims to transform stroke care by minimizing disability and improving post-stroke quality of life through innovative medical devices [2][6] - The company was established in 2017 in collaboration with The Trendlines Group and the Israel Innovation Authority [6] Study Results - A multicenter, single-arm study involving 20 patients showed that the Ceretrieve device achieved 100% Complete/Near-Complete Perfusion in all treated patients using the improved Gen 2 device [4] - The device achieved an 83% First Pass Complete Perfusion rate, significantly higher than the 30%-40% rate of current gold-standard devices [4][3] Device Features - The aspiration catheter is designed for seamless integration with conventional delivery systems, offering exceptional trackability and maneuverability [2][5] - The device features a giant bore tip that enhances vacuum effect while maintaining trackability, and it provides local flow restriction to reduce distal emboli [5] Clinical Impact - The first pass effect of the Ceretrieve device has been shown to improve patient outcomes, enabling complete clot ingestion even in challenging cases [5] - The advanced technology of Ceretrieve is setting a new standard in stroke care, leading to significant improvements in patient recovery rates [5]